SOPHiA GENETICS Provides Preliminary Fourth Quarter and Full Year 2025 Financial Results, Initiates 2026 Guidance, and Announces Executive Transition Plan

About this update from Sophia Genetics Sa

[{"type":"text","content":"The Company finishes 2025 with strong Q4 performance, expects 20-22% revenue growth in 2026, and promotes Ross Muken to CEO","length":123,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON and ROLLE, Switzerland, Jan. 12, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today provided preliminary unaudited financial results for the fourth quarter and full year 2025, initiated its financial outlook for 2026, and announced an executive transition plan, including the promotion of Ross Muken to Chief Executive Officer (CEO), effective July 1, 2026, and the transition of co-Founder Jurgi Camblong to Executive Chairman.","length":497,"tagName":"p"},{"type":"image","alt":"SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)","displaySize":"","headline":null,"caption":"SOPHiA GENETICS Logo (PRNewsfoto/SOPHiA GENETICS)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n6kFaeXBXi.jQBj8QTEY9A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7af8bf13f8f939ef861dc0027929881b","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Fourth Quarter 2025 Preliminary Unaudited Financial Results","length":59,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of at least $21 million, representing an increase of approximately 20% year-over-year","length":93,"tagName":"p"}]},{"val":[{"type":"text","content":"Performed over 105,000 analyses on SOPHiA DDM™ in the fourth quarter, representing 16% year-over-year growth","length":113,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":206,"olType":false},{"type":"text","content":"Full Year 2025 Preliminary Unaudited Financial Results","length":54,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of approximately $77 million, representing an increase of approximately 18% year-over-year","length":98,"tagName":"p"}]},{"val":[{"type":"text","content":"Performed over 391,000 analyses on SOPHiA DDM™ in 2025, a new company record","length":81,"t...

More updates from Sophia Genetics Sa